Biomarker-driven medical research involving adults who have or are at risk of developing cancer
1400+ member research sites
Joined November 2013
- Tweets9.6K
- Following2.5K
- Followers6.7K
- Likes3.9K
Pinned Tweet
The #EAOnc Fall 2026 Group Meeting officially begins today! Looking forward to seeing you in Philadelphia. Check in at the registration desk on the 5th floor before heading to your first session. 🩺
ECOG-ACRIN Cancer Research Group retweeted
Very interesting and pertains to myeloma even more.
Dr. Mark Rocschewski @MSKCancerCenter presenting at @eaonc Heme Malignancy session showed this interesting slide pertaining to large cell lymphoma.
Patients who clear circulating tumor DNA of course do well. But what’s interesting is 25% of patients with detectable circulating tumor DNA have no recurrence. A real plateau!
Residual ctDNA (or MRD) may not necessarily mean bad outcome.
Do you have early-stage #melanoma and are age 75 or older? If so, you may be eligible to participate in this study of a potential new treatment approach. More info: bit.ly/ea6244-study #SkinCancer #MelanomaResearch
Congratulations to Dr. Bob Gray of @HarvardChanSPH @DanaFarber on his retirement as @eaonc Group Statistician! 🎉 We’re grateful for his many contributions to the #CancerResearch community. Wishing him all the best in this next chapter!
ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer | EA2251 will be led by Deirdre Cohen @TischCancer and supported by @theNCI and @SMMT_TX
ecog-acrin.org/press-release… – at Philadelphia, PA
ECOG-ACRIN Cancer Research Group retweeted
Respect to amazing legend in biostatistics Bob Gray who has transformed the field of biostatistics with huge impact in oncology globally! Wonderful to see #NancyDavidson @fredhutch @jsparano @AACRPres & others commenting on his career! Congrats on retirement!
@eaonc
@VincentRK
Do you have advanced #cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: bit.ly/ComboMATCH
ECOG-ACRIN Cancer Research Group retweeted
Fantastic to watch @eaonc general session with amazing speakers @AACR_CEO & other leaders sitting next to @VincentRK who has transformed the field in multiple myeloma! Always inspired to be with global leaders as we work together to create vision & move field forward @OncoAlert
ECOG-ACRIN Cancer Research Group retweeted
My colleague @myelomaMD is presenting the results of the ENDURANCE randomized trial at General Session of ECOG-ACRIN group meeting. This trial showed 2 years of lenalidomide maintenance provides same survival as indefinite maintenance in standard risk myeloma. @eaonc @NEJM
A very Philadelphia General Session at our Fall 2026 Group Meeting. Delighted to be joined by @AACR_CEO of @AACR and Cancer Center Directors Dr. Vonderheide of @PennCancer, Dr. Chapman of @KimmelCancerCtr & @DrRobWinn of @FoxChaseCancer! #CancerResearch
Congratulations to the Fall 2026 Edith Peterson Mitchell, MD Health Equity Travel Scholars: Kamryn Clay, @belladreyfuss25, Dr. Ekpenyong, Dr. Gabra, Alaina Hawkins, @xlabissieremd, @dan_morgen, @PhyuNaing4, @OgaKingsley, & Kennedy Stacy #CancerResearch #ClinicalTrials #eaonc
The Fall 2026 Comis #TranslationalScience Symposium concludes w/ a fantastic panel discussion ft. @MoghaddamSeyed & @humam_kadara of @UTMDAnderson, @tonyrcillo of @UPMCHillmanCC, Drs. Beatty & McDonald of @PennCancer, Dr. Gropler of @washumedicine, & @JaniceM10 of @Perlmutter_CC
The Fall 2026 Comis #TranslationalScience Symposium continues with talks by Dr. Beatty of @PennCancer & Dr. Gropler of @washumedicine @WashUMedMIR #CancerResearch #Inflammation
The Robert L. Comis, MD #TranslationalScience Symposium has begun with great talks on "#Inflammation as a Shared Mechanism Across Diseases" by @MoghaddamSeyed & @humam_kadara of @UTMDAnderson & @tonyrcillo of @UPMCHillmanCC #eaonc
Congratulations to the early-career researchers selected to present at our annual Young Investigator Symposium! Great session this morning! Cc: @JithmaA @FahminB_MDPhD @FedGhali @Jani_Chinmay @CathyHandy @ShachiMittal2 @fangdisun @VarshaS53228024 #eaonc #CancerResearch
The #BreastCancer study EA1242/RxFINE-Low is testing whether #HormoneTherapy plus ribociclib, without #Chemotherapy, is as effective as standard treatment that includes chemotherapy. Learn more: bit.ly/ea1242-study #BCSM #BreastCancerAwareness
ECOG-ACRIN Cancer Research Group retweeted
Our hematologist Dr. Jithma Abeykoon cares for people with lymphoma and histiocytic cancers and conducts research focused on understanding and delineating disease biology and discovering new treatment strategies for individuals with these cancers: mayo.edu/research/faculty/ab….
Meet the 2026 ECOG-ACRIN Young Investigator Symposium presenters, who will share innovative #CancerResearch tomorrow in Philadelphia: bit.ly/YIS26
@JithmaA @FahminB_MDPhD @FedGhali @Jani_Chinmay @CathyHandy @ShachiMittal2 @fangdisun @VarshaS53228024 & Allison Matous
#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart of @URMed_DeptMed & @WilmotCancer, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM
ECOG-ACRIN Cancer Research Group retweeted
Thank you ECOG-ACRIN for this opportunity! Looking forward! :)
Meet the 2026 ECOG-ACRIN Young Investigator Symposium presenters, who will share innovative #CancerResearch tomorrow in Philadelphia: bit.ly/YIS26
@JithmaA @FahminB_MDPhD @FedGhali @Jani_Chinmay @CathyHandy @ShachiMittal2 @fangdisun @VarshaS53228024 & Allison Matous